Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Author's Avatar
May 11, 2023

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the first quarter ended March 31, 2023, and provided clinical development and operational highlights.